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We thank Prof. Undas for her interest in our recent 
article and comments on left atrial appendage occlusion 
[1]. We agree that our study indirectly points to potential 
benefits of non-vitamin K oral anticoagulants’ (NOAC) 
use in selected atrial fibrillation (AF) patients following 
left atrial appendage occlusion (LAAO) in the setting of 
high thromboembolic and bleeding risk, but a dedicated 
study is urgently needed to support this concept. Several 
points need to be discussed. 
We presented the real-life observational data on dif-
ferent anticoagulation strategies in atrial fibrillation (AF) 
patients after LAAO using the LARIAT system between 
2009 and 2015 [1]. During this period, the guidelines 
on oral anticoagulation in AF shifted towards the novel 
drugs. NOACs were approved in adults with non-valvular 
AF at the end of 2011, and 18% of patients studied by us 
received drugs from this group at the end of the study 
(2015). We observed a progressive increase in NOAC use 
starting from 2012–2013, which is in concordance with 
other Polish data [2]. The fraction of patients receiving 
NOACs is rather small, which may be a result of the rel-
ative unfamiliarity of LAAO procedure  concepts, and/or 
reluctance to use drugs new to the market. 
Unfortunately, detailed data on the quality of antico-
agulation were unavailable in the current report, but poor 
quality of anticoagulant therapy is a well-known problem 
in AF patients. In Poland, the time within the therapeutic 
range (TTR) in primary care patients on vitamin K antag-
onist (VKA) therapy is around 55% [3], and some of the 
observed adverse events may, arguably, be caused by 
poor VKA anticoagulation management. Two hemorrhag-
ic strokes were observed in non-anticoagulated patients 
and were probably caused by uncontrolled hypertension. 





of 6 points and a HAS-BLED score of 3 points, was man-





VASc score of 2 points and a HAS-BLED score of 2 points, 
no anticoagulation or antiplatelet drugs were given. In 
the OAC group a  hemorrhagic stroke occurred in 1 pa-




-VASc score of 2 points and 
a HAS-BLED score of 3 points, who had INR > 3.5 (after 
this event, anticoagulation was discontinued complete-
ly). There was also one case of gastrointestinal bleeding 





of 6 points and a HAS-BLED score of 5 points (the dose 
of dabigatran was reduced after the event). In terms of 
thromboembolic events (two strokes and one peripheral 
embolism), all occurred during VKA therapy, and antico-
agulation therapy was switched to NOACs in all cases.
Although older age is listed as a risk factor for both 
bleeding and thromboembolism, we did not find a rela-
tionship with the incidence of adverse events, which is 
in line with our previous study [4]. It would be of interest 
to conduct a randomized trial comparing LAAO with no 
subsequent anticoagulation versus different anticoagu-
lation strategies. It cannot be excluded that in individuals 
with high both thromboembolic and bleeding risk, LAAO 
with subsequent reduced-dose NOAC may be an optimal 
treatment strategy (in the setting of no absolute contra-
indications). 
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